NCT04534270View on ClinicalTrials.gov

Efficacy and Safety of Dapagliflozin in Children With Proteinuria

PHASE4CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

July 6, 2020

Primary Completion Date

December 30, 2021

Study Completion Date

March 30, 2022

Conditions
Proteinuria
Interventions
DRUG

Dapagliflozin

Dapagliflozin will be given 5mg per day (weight≤30kg) or 10mg per day (weight\>30kg), for 12 weeks

Trial Locations (1)

201102

Children's Hospital of Fudan University, Shanghai

All Listed Sponsors
lead

Children's Hospital of Fudan University

OTHER

NCT04534270 - Efficacy and Safety of Dapagliflozin in Children With Proteinuria | Biotech Hunter | Biotech Hunter